Avosentan for overt diabetic nephropathy.

  title={Avosentan for overt diabetic nephropathy.},
  author={Johannes F. E. Mann and Damian Green and Kenneth A. Jamerson and Luis M Ruilope and Susan J Kuranoff and Thomas Littke and Giancarlo Viberti},
  journal={Journal of the American Society of Nephrology : JASN},
  volume={21 3},
In the short term, the endothelin antagonist avosentan reduces proteinuria, but whether this translates to protection from progressive loss of renal function is unknown. We examined the effects of avosentan on progression of overt diabetic nephropathy in a multicenter, multinational, double-blind, placebo-controlled trial. We randomly assigned 1392 participants with type 2 diabetes to oral avosentan (25 or 50 mg) or placebo in addition to continued angiotensin-converting enzyme inhibition and… CONTINUE READING
Highly Influential
This paper has highly influenced 11 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS
131 Extracted Citations
23 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 131 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 23 references

Do endothelin receptor antagonists induce edema through extravasation of fluids

  • M Maillard, Q Wang, O Baltatu, M Burnier
  • J Hypertens 26[Suppl
  • 2009

Efficacy and safety of darusentan: A novel endothelin receptor antagonist

  • BJ Epstein
  • Ann Pharmacother
  • 2008

Similar Papers

Loading similar papers…